Product logins

Find logins to all Clarivate products below.


Blog: Market Access

Here you will find relevant articles and insight into all Clarivate related products and news.

Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Biopharma Commercialization GLP-1
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Commercialization Consulting Resource Center
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials
Key market access considerations for long-acting and alternative delivery therapies Key market access considerations for long-acting and alternative delivery therapies
Blog February 20, 2026
Key market access considerations for long-acting and alternative delivery therapies
Biopharma Commercialization Consulting Resource Center
The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies
Biopharma Commercialization Consulting Resource Center

Market Access

A Life Sciences case study from the heart of Europe A Life Sciences case study from the heart of Europe
Blog February 22, 2024
A Life Sciences case study from the heart of Europe
Blog July 19, 2019
Moving Forward From Medicare Part D Rebate Reform
Blog June 25, 2018
Under ISP, How Will your Plan Assess an Oncology Drug’s Value for an Indication?
Blog May 9, 2018
Medicare Advantage leader eyes 50 percent penetration — but when?
Blog June 29, 2017
Direct-to-consumer: New avenue for PBMs could provide political shelter
Blog March 30, 2017
Outcomes-Based Contracting Gain Steam